QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
OTCMKTS:CPMD

CannaPharmaRX (CPMD) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)
Free CPMD Stock Alerts
$0.01
0.00 (0.00%)
(As of 04/18/2024 ET)
Compare
Today's Range
$0.01
▼
$0.01
50-Day Range
$0.00
▼
$0.02
52-Week Range
$0.00
▼
$0.03
Volume
N/A
Average Volume
980,252 shs
Market Capitalization
$6.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest
CPMD stock logo

About CannaPharmaRX Stock (OTCMKTS:CPMD)

CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.

CPMD Stock Price History

CPMD Stock News Headlines

March 14, 2024 | finanznachrichten.de
Cannapharmarx, Inc.: CannapharmaRx Receives First Purchase Order and Begins Shipment of Product
March 12, 2024 | finanznachrichten.de
CannaPharmaRx, Inc.: CannaPharmaRx Completes First Harvests
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
March 7, 2024 | finanznachrichten.de
Cannapharmarx, Inc.: CannaPharmaRx to Hold Investor Conference Call
March 5, 2024 | msn.com
Cannapharmarx Partners With ICAN To Expand Cannabis Distribution In Latin America
March 5, 2024 | finanznachrichten.de
Cannapharmarx, Inc.: CannaPharmaRx Executes Multi-Year Supply Agreement with ICAN to Create Distribution Network in the Latin Americas
February 23, 2024 | finanznachrichten.de
Cannapharmarx, Inc.: CannaPharmaRx Achieves IMC-GAP and GACP Certifications Completing a Significant Milestone Towards Revenue Acceleration
February 16, 2024 | finanznachrichten.de
Cannapharmarx, Inc.: CannaPharmaRx Finalizes Multi-Million Dollar Israeli Supply Agreement with Cantek
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
February 16, 2024 | finance.yahoo.com
CannaPharmaRx Finalizes Multi-Million Dollar Israeli Supply Agreement with Cantek
February 15, 2024 | finanznachrichten.de
Cannapharmarx, Inc.: CannaPharmaRx CEO Provides Annual Update Message
February 15, 2024 | stockhouse.com
CannaPharmaRx CEO Provides Annual Update Message
September 10, 2023 | finance.yahoo.com
CannaPharmaRX, Inc. (CPMD) Stock Historical Prices & Data - Yahoo Finance
August 25, 2023 | finanznachrichten.de
Cannapharmarx, Inc.: CannaPharmaRx Expands Board of Directors
August 25, 2023 | finance.yahoo.com
CannaPharmaRx Expands Board of Directors
June 23, 2023 | finance.yahoo.com
CannaPharmaRx Appoints Dean Medwid as New CEO
April 19, 2023 | finance.yahoo.com
CannaPharmaRx Signs Agreement with Nasha Genetics
April 4, 2023 | uk.finance.yahoo.com
CannaPharmaRX, Inc. (CPMD) stock historical prices & data – Yahoo Finance
March 30, 2023 | finance.yahoo.com
CannaPharmaRx Signs Supply Agreement with Y.S.A Holdings for up to $15 Million Annually of Commercial Cannabis
March 21, 2023 | finance.yahoo.com
CannaPharmRx, Inc. Completes Purchase of LTB Management, an E- Commerce and Financial Platform Company, and Launches New Corporate Website
February 21, 2023 | finance.yahoo.com
CannaPharmRx, Inc. Adds to Revenue Streams by Purchasing E-Commerce and Financial Platform Company
February 1, 2023 | finance.yahoo.com
CannaPharmaRx Evaluates Investigation into Market Manipulation and Potentially Illegal Trading of Stock
January 30, 2023 | finance.yahoo.com
CannaPharmaRx Releases Year-in-Review Letter to Shareholders and Discusses Revenue Opportunities for 2023
January 11, 2023 | finance.yahoo.com
CannaPharmaRx Receives Canada Revenue Agency (CRA) License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million Expected
December 22, 2022 | finance.yahoo.com
Canadian Cannabis; Down but Far from Out - Growth for 2023 and Beyond
December 21, 2022 | finance.yahoo.com
CannaPharmaRx Receives Cultivation License from Health Canada and Projects 2023 Annual Revenue over $30 Million
December 21, 2022 | finance.yahoo.com
CannaPharmaRx Receives Cultivation License from Health Canada and Projects 2023 Revenue Over $30 Million
See More Headlines
Receive CPMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CannaPharmaRX and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:CPMD
CUSIP
N/A
CIK
1081938
Web
www.cannapharmarx.com
Phone
(949) 652-6838
Fax
720-875-1905
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,530,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-141.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
-0.14

Miscellaneous

Outstanding Shares
660,630,000
Free Float
652,236,000
Market Cap
$6.61 million
Optionable
Not Optionable
Beta
2.12
The Best High-Yield Dividend Stocks for 2024 Cover
The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Dominick Colvin (Age 55)
    President & Director
    Comp: $94.65k
  • Mr. Dean P. Medwid (Age 56)
    Chief Executive Officer
  • Mr. Oliver W. Foeste C.A. (Age 48)
    CPA, Chief Financial Officer

Key Competitors

View All Competitors

CPMD Stock Analysis - Frequently Asked Questions

How have CPMD shares performed in 2024?

CannaPharmaRX's stock was trading at $0.0017 at the start of the year. Since then, CPMD stock has increased by 488.2% and is now trading at $0.01.
View the best growth stocks for 2024 here.

Are investors shorting CannaPharmaRX?

CannaPharmaRX saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,900 shares, an increase of 26.7% from the March 15th total of 1,500 shares. Based on an average trading volume of 3,469,700 shares, the short-interest ratio is currently 0.0 days.
View CannaPharmaRX's Short Interest.

What other stocks do shareholders of CannaPharmaRX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CannaPharmaRX investors own include Curaleaf (CURLF), Aimmune Therapeutics (AIMT), Refined Metals (CADMF), KushCo (KSHB), Dynavax Technologies (DVAX), GW Pharmaceuticals (GWPH), Organigram (OGI) and AIM ImmunoTech (AIM).

How do I buy shares of CannaPharmaRX?

Shares of CPMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CPMD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media